Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 83.86% is in line with its 4-year average of 83.00%, around the middle of its 4-year range (73.58%–92.31%).
0.25% above its 12-month average of 83.65%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 85.71%.
GROSS MARGIN
83.86%
GROSS MARGIN AVG TTM
83.65%
GROSS MARGIN AVG 3Y
83.03%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.25%
CURRENT VS 3Y AVG
+1.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+102.66%
vs the sector median at left
Indivior Pharmaceuticals Inc
Market Cap
$4.43B
Gross Margin
83.86%
TTM Avg
83.65%
3Y Avg
83.03%
5Y Avg
N/A
Market Cap
$4.44B
Gross Margin
80.08%
TTM Avg
75.94%
3Y Avg
72.82%
5Y Avg
72.82%
Market Cap
$4.40B
Gross Margin
75.44%
TTM Avg
66.98%
3Y Avg
64.58%
5Y Avg
67.25%
Market Cap
$4.29B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.65B
Gross Margin
18.17%
TTM Avg
19.16%
3Y Avg
20.78%
5Y Avg
21.38%
Market Cap
$4.68B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.68B
Gross Margin
33.56%
TTM Avg
32.27%
3Y Avg
30.18%
5Y Avg
31.09%
Market Cap
$4.71B
Gross Margin
96.01%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$4.70B
Gross Margin
71.27%
TTM Avg
60.67%
3Y Avg
48.49%
5Y Avg
48.49%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indivior Pharmaceuticals Inc (INDV) | $4.43B | 83.86% | 83.65% | 83.03% | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.44B | 80.08% | 75.94% | 72.82% | 72.82% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.40B | 75.44% | 66.98% | 64.58% | 67.25% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.29B | 0.00% | 0.00% | 0.00% | 0.00% |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 18.17% | 19.16% | 20.78% | 21.38% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.68B | 0.00% | 0.00% | 0.00% | 0.00% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 33.56% | 32.27% | 30.18% | 31.09% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.71B | 96.01% | 100.00% | 100.00% | 83.33% |
| BillionToOne, Inc. (BLLN)vs › | $4.70B | 71.27% | 60.67% | 48.49% | 48.49% |
| LivaNova PLC (LIVN)vs › | $4.14B | 68.18% | 68.59% | 68.31% | 67.52% |
Gross Margin
83.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 85.71% |
| 2026-03-31 | 87.38% |
| 2025-12-31 | 82.12% |
| 2025-09-30 | 80.25% |
| 2025-06-30 | 82.78% |
| 2025-03-31 | 83.46% |
| 2024-12-31 | 92.31% |
| 2024-09-30 | 77.52% |
| 2024-06-30 | 73.58% |
| 2024-03-31 | 86.62% |
| 2023-12-31 | 82.59% |
| 2023-09-30 | 83.03% |
| 2023-06-30 | 81.88% |
| 2023-03-31 | 84.58% |
| 2022-12-31 | 81.82% |
| 2022-09-30 | 82.76% |
| 2022-06-30 | 82.81% |
| 2022-03-31 | 82.13% |
| 2021-12-31 | 82.51% |
